Three years ago, 23andMe, the DNA-testing firm, was celebrated for its innovative approach to genetic testing, boasting a share price that even surpassed that of tech giant Apple. However, the company now finds itself in a precarious situation, grappling with a significant decline in share price and the threat of being delisted from the stock market.

Once a leader in the booming DNA testing market, 23andMe attracted millions of customers eager to explore their ancestry and genetic predispositions. Celebrities like Snoop Dogg and Oprah Winfrey helped fuel its popularity, with the company’s stock peaking at $321. Fast forward to today, and its share price has plummeted to just under $5, reducing its market value to a mere 2% of its former worth.

The Downfall

Experts attribute 23andMe’s decline to two main factors. Firstly, the company struggled to establish a sustainable business model. After customers received their DNA reports, there was little incentive for them to return for additional services. Secondly, the timeline for monetizing its vast DNA database for drug research proved too lengthy. The drug development process is notoriously slow, leading to a stagnation in potential revenue streams.

Professor Dimitris Andriosopoulos from Strathclyde University suggests that 23andMe’s survival is uncertain. “If I had a crystal ball, I’d say they will maybe last for a bit longer,” he stated, expressing skepticism about the company’s ability to rebound.

The turmoil within the company’s leadership further complicates its situation. After the board resigned in the summer, only CEO and co-founder Anne Wojcicki remains from the original team. Speculation about the company’s future has intensified, with rumors of a potential sale circulating, despite Wojcicki’s intentions to take the company private.

Data Privacy Concerns

The implications of 23andMe’s decline extend beyond financial metrics; they raise serious questions about data privacy. The firm possesses highly sensitive genetic data from its customers, including their family members, which could be misused if the company undergoes significant changes or fails entirely.

Carissa Veliz, author of Privacy is Power, highlights the unique risks associated with DNA data. Unlike traditional personal data, DNA information cannot be changed or replaced. If a customer’s genetic data is compromised, it poses a threat not only to them but also to their relatives who did not consent to sharing their genetic information.

23andMe has maintained that it is committed to protecting customer data and privacy. The company asserts that any future ownership changes would adhere to applicable data protection laws and that its terms of service would remain intact unless customers agree to new terms. However, past breaches—such as a hack that occurred a year ago—have heightened concerns regarding the company’s ability to safeguard its sensitive database.

The Future of Genetic Data

As 23andMe navigates these challenges, experts like Veliz argue for a more robust regulatory framework to protect personal data. “Until we ban the trade in personal data, we are not well protected enough,” she warns, advocating for stricter privacy regulations.

While 23andMe aims to reassure its customers, the intersection of corporate struggles and data privacy poses significant risks. The fate of the company and the security of its genetic database remain uncertain as it faces mounting pressure from both the market and ethical considerations surrounding data handling in the tech industry.